Precis Future Med Search

CLOSE


Precis Future Med > Epub ahead of print
DOI: https://doi.org/10.23838/pfm.2020.00114    [Epub ahead of print]
Published online October 13, 2020.
Validation of new TRUS biopsy techniques for PI-RADS 4 or 5
Taein An  , Byung Kwan Park 
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence  Byung Kwan Park ,Tel: +82-2-3410-6457, Email: rapark@skku.edu
Submitted: July 30, 2020  Accepted after revision: September 11, 2020
Abstract
Purpose
Recently, new magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) techniques and imaging features of Prostate Imaging and Report and Data System (PI-RADS) 4 or 5 have been reported. The aim of this study was to validate the outcomes of new TRUS-guided biopsy techniques for cancer detection in patients with PI-RADS 4 or 5.
Methods
Between June 2018 and November 2018, 94 men underwent TRUS-guided biopsy after PI-RADS 4 (n= 59) or 5 (n= 35) was categorized as an index lesion on MRI. For PI-RADS 4 group, target biopsy was performed in 5 and combination biopsy (target and systematic biopsies) was in 54. For PI-RADS 5 group, target biopsy was performed in 19 and combination biopsy was in 16. Target to combination biopsy ratios and significant cancer detection rates (CDRs) were compared between the groups. Significant cancer was defined as a Gleason score ≥ 7 tumor. Standard reference was biopsy examination. Fisher’s exact were used for statistical analysis.
Results
Target to combination biopsy ratios was 5:54 in the PI-RADS 4 group and 19:16 in the PI-RADS 5 group (P< 0.0001). The significant CDR of the target biopsy were 42.4% (25/59) in the PI-RADS 4 group and 82.6% (29/35) in the PI-RADS 5 group (P= 0.0002). The significant CDR of combination biopsy was 44.1% (26/59) in the PI-RADS 4 group and 85.7% (30/35) in the PI-RADS 5 group (P< 0.0001).
Conclusion
New TRUS biopsy techniques provides high significant CDR patients with PI-RADS 4 or 5. Therefore, TRUS should be performed prior to fusion or in-bore biopsy to determine if these categories are visible.
Keywords: Biopsy; Prostate; Ultrasonography
TOOLS
Share :
Facebook Twitter Linked In Google+
METRICS Graph View
  • 0 Crossref
  •    
  • 36 View
  • 1 Download


ABOUT
ARTICLES

Browse all articles >

ISSUES
TOPICS

Browse all articles >

EDITORIAL
POLICY
AUTHOR
INFORMATION
Editorial Office
Sungkyunkwan University School of Medicine
115 Irwon-ro, Gangnam-gu, Seoul 06355, Korea
Tel: +82-2-3410-6939    Fax: +82-2-2148-9919    E-mail: pfmjournal@skku.edu                

Copyright © 2020 by Sungkyunkwan University School of Medicine. All rights reserved.

Developed in M2community

Close layer
prev next